Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Hepatitis C virus therapies: current treatments, targets and future perspectives Walker MP; Appleby TC; Zhong W; Lau JY; Hong ZAntivir Chem Chemother 2003[Jan]; 14 (1): 1-21Chronic hepatitis C virus (HCV) infection is the cause of an emerging global epidemic of chronic liver disease. Current combination therapies are at best 80% efficacious and are often poorly tolerated. Strategies to improve the therapeutic response include the development of novel interferons, nucleoside analogues with reduced haemolysis compared with ribavirin and inosine 5'-monophosphate dehydrogenase inhibitors. Compounds in preclinical or early clinical trials include small molecules that inhibit virus-specific enzymes (such as the serine proteases, RNA polymerase and helicase) or interfere with translation (including anti-sense molecules, iRNA and ribozymes). Advances in understanding HCV replication, obtaining a sub-genomic replicon and contriving potential small animal models, in addition to solving crystallographic structures for the replication enzymes, have improved prospects for developing novel therapies. This review summarizes current and evolving treatments for chronic hepatitis C infection. In addition, progress in HCV targets and drug discovery tools valuable in the search for novel anti-HCV agents is detailed.|Animals[MESH]|Antiviral Agents/chemistry/*therapeutic use[MESH]|Clinical Trials as Topic[MESH]|Disease Models, Animal[MESH]|Drug Design[MESH]|Drug Therapy, Combination[MESH]|Enzyme Inhibitors/therapeutic use[MESH]|Hepacivirus/*drug effects[MESH]|Hepatitis C, Chronic/*drug therapy/prevention & control[MESH]|Humans[MESH]|Interferon-alpha/therapeutic use[MESH]|Recombinant Proteins/therapeutic use[MESH]|Ribavirin/therapeutic use[MESH] |
